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Crystal structure and functional dissection of the cytostatic
cytokine oncostatin M
Marc C Deller1,2†#, Keith R Hudson2‡#, Shinji Ikemizu1, Jerónimo Bravo1§,
E Yvonne Jones1* and John K Heath2
Background: The cytokine oncostatin M (OSM) inhibits growth of
certain tumour-derived cells, induces proliferation in other cell types
(e.g. haemangioblasts) and is a mediator of inflammatory responses. Its
mechanism of action is via specific binding to gp130 and either the leukaemia
inhibitory factor receptor (LIFR) or oncostatin M receptor (OSMR) systems
at the cell surface to form an active signalling complex.
Results: We report here the crystal structure of human oncostatin M (hOSM)
along with mutagenesis data which map the receptor-binding epitopes of the
molecule. The structure was determined to a resolution of 2.2 Å and conforms
to the haematopoietin cytokine up-up-down-down four-helix bundle topology.
The site 2 epitope, responsible for gp130 binding, is centred around Gly120
which forms a ‘dimple’ on the surface of the molecule located on helices A and
C. The site 3 motif, responsible for LIFR and OSMR binding, consists of a
protruding Phe160/Lys163 pair located at the start of helix D. 
Conclusions: The data presented allow functional dissection of the
receptor-binding interfaces to atomic resolution. Modelling suggests that the
gp130 residue Phe169 packs into the site 2 dimple in an analogous fashion
to structurally equivalent residues at the growth hormone–growth hormone
receptor interface, implying that certain key features may underlie recognition
across the whole cytokine/receptor superfamily. Conversely, detailed
comparison of the available structures suggests that variations on a common
theme dictate the specificity of receptor–ligand interactions within the gp130
family of cytokines.
Introduction
Human oncostatin M (hOSM) is a secreted 252 amino acid
polypeptide cytokine that was originally isolated by virtue
of its ability to suppress the proliferation of human
melanoma cells in vitro [1]. Subsequent biological investiga-
tions have revealed that hOSM and mouse OSM (mOSM)
exhibit a diversity of effects on different target cell types.
These include the ability to inhibit the multiplication of a
variety of different tumour-derived cell lines (reviewed in
[2]) as well as inducing the proliferation of certain cells
including Kaposi sarcoma-derived spindle cells [3] and hae-
mangioblasts derived from the aorta–gonad–mesonephros
region of the developing embryo [4]. hOSM, released from
macrophages and neutrophils [5], has also been implicated
as an important mediator of pro-inflammatory responses in
joint destruction [6] and central nervous system inflamma-
tion and neurodegeneration [7,8] via, inter alia, the induc-
tion of acute- phase protein gene expression [9,10].
hOSM is a member of the family of gp130 cytokines that
are characterised by the use of the shared transmembrane
transducing receptor gp130 in their mechanism of action
[11]. hOSM is therefore functionally related to leukemia
inhibitory factor (LIF), interleukin (IL)-6 and IL-11, car-
diotrophin-1 (CT-1) and ciliary neurotrophic factor
(CNTF). A key feature of the gp130 cytokines is that
intracellular signalling results from the ligand-mediated
formation of oligomeric receptor complexes which,
depending upon the identity of the ligand, can differ in
both composition and stoichiometry [12]. In all cases,
however, receptor complexes include one or more mol-
ecules of the shared transducer gp130 [13]. gp130
cytokines can therefore exhibit both unique and shared
biological activities in vivo and in vitro depending upon the
composition of the receptor signalling complex that is
formed [11]. hOSM signals via formation of an active
receptor signalling complex that comprises gp130 and one
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of two partner receptors: either the LIF receptor (LIFR)
[14] or the structurally related OSM-specific receptor,
OSMR [15]. mOSM [16] differs from hOSM in that it only
signals via association with gp130 and the murine OSMR
[17,18]; this means that there is a significant divergence in
action between mOSM and hOSM and that the LIFR
recognition elements of OSM are not conserved. This
finding also indicates that the unique biological activities
of hOSM, such as cytostatic effects on tumour cells, are
mediated via association with OSMR. Those activities of
hOSM that are shared with other cytokines, such as LIF or
CNTF, may reflect a common association with the LIFR.
Knowledge of the structural basis of receptor recognition
by gp130 cytokines is a central issue in understanding both
the specificity of their biological functions and developing
methods for therapeutic intervention in gp130-mediated
signalling. The crystal structures of three gp130 cytokines,
LIF [19], CNTF [20] and IL-6 [21], have been previously
described. These reveal that all three cytokines share a
common three-dimensional fold, the four-helix bundle
[22], which comprises four α helices ranging from 15 to 22
amino acids in length (termed A, B, C and D) and linked
by polypeptide loops. Detailed structure–function studies
of human LIF, which is most closely related to hOSM in
sequence and receptor repertoire, have defined two recep-
tor recognition epitopes: sites 2 and 3. Site 2 (so-termed by
analogy to the receptor-binding sites in growth hormone
[23]), is required for recognition of gp130 and has been
narrowed down to a cluster of candidate amino acid
residues located in helices A and C [24]. Site 3 is required
for recognition of LIFR and is dominated by a pair of con-
served amino acid residues located at the N-terminal tip of
helix D [24]. The combined activity of these two recogni-
tion epitopes leads to the formation of a trimeric, LIF-
mediated, high-affinity signalling complex [24]. 
Structural comparisons of ligands with differing recognition
properties present a valuable opportunity to analyse the
molecular determinants that dictate receptor specificity.
Here, we report the determination of the three-dimensional
structure of hOSM by crystallographic techniques and con-
comitant functional dissection by mutagenesis. Because
hOSM binds to gp130 with a higher affinity than LIF [24],
this allows structure–function analysis of the site 2 gp130
recognition epitope at the resolution of individual amino
acid residues. Combining these findings with the high-reso-
lution crystal structure of the complementary ligand-recog-
nition epitope located in the cytokine receptor homology
domain (CHD) of gp130 [25] results, for the first time, in a
definition of the structure of the interface between hOSM
and gp130. In addition a detailed comparison of the three-
dimensional structure of the site 3 recognition epitope of
hOSM and hLIF also offers insights into the molecular
basis by which related ligands exhibit different receptor
recognition properties. These findings reveal that, in both
cases, receptor specificity is controlled by subtle structural
changes to a common recognition framework.
Results
Expression and structure determination
A soluble 21.4 kDa fragment of hOSM was expressed in
Escherichia coli as a glutathione-S-transferase (GST) fusion
protein. The resulting purified protein consists of residues
1–187 of hOSM and a further four residues at the N termi-
nus corresponding to the 3C protease site linker (GPGS).
Ba/F3 cell-survival assays and receptor-binding assays con-
firmed that this recombinant form binds gp130 with an
affinity equivalent to wild-type (WT) hOSM. 
Crystallisation trials produced Bragg diffraction quality
crystals belonging to the orthogonal space group P212121,
with unit-cell dimensions a = 35.8 Å, b = 53.1 Å, c = 106.8 Å.
The structure was determined from a single ethylmer-
curyphosphate (EMP) derivative using the multiple
anomalous dispersion (MAD) phasing technique with
X-ray diffraction data collected on beam line BM14 of the
European Synchrotron Radiation Facility (ESRF). The
structure has been refined to a crystallographic R factor of
20.5% (Rfree 26.1%) for all data between 20.0 and 2.2 Å,
with stereochemistry typified by root mean squared devia-
tions (rmsd) in bond lengths of 0.015 Å and in bond angles
of 1.8°. Crystallographic statistics are reported in Tables 1
and 2. Residues 1–3 and 135–155 appear to be disordered
and are not included in the final model. With the excep-
tion of these regions, and a flexible loop between residues
Glu90 and Lys110, the electron density is good through-
out the course of the mainchain (a representative portion
of electron density is shown in Figure 1a). Residue num-
bering is that of the human native mature protein
(GenBank accession number M27286).
Structure description 
hOSM is a compact barrel-shaped molecule with dimen-
sions of approximately 20 Å × 27 Å × 56 Å that conforms
to the up-up-down-down four-helix bundle topology
(Figure 1b,c). The basic fold consists of the four main
helical regions (helix A, residues 10–37; helix B, residues
67–90; helix C, residues 105–131; helix D, residues
159–185) connected by two long overhand loops (AB loop,
residues 38–66; CD loop, residues 130–158) and one short
loop (BC loop, residues 91–104). The overall arrangement
may be considered as two pairs of antiparallel helices that
pack together, with A–D forming one pair and B–C
forming the other. 
Both helices A and C exhibit breaks in the classical hydro-
gen-bonding pattern, with substitute hydrogen bonds
formed to tightly bound water molecules. In helix C this
results in a slight kink (between residues Gln112 and
Pro116). The kink in helix A is more pronounced and is
caused by a break in the helical conformation, as residues
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Gln25 and Leu30 adopt a hydrogen-bonded turn confor-
mation, with four tightly bound water molecules substitut-
ing for the classical hydrogen-bonding pattern (Figure 1a).
Residues Thr27–Ile37 of helix A adopt a 310 helix confor-
mation. The curved nature of helices A and C facilitates
close packing of the A–D and B–C helix pairs, so promot-
ing an extensive solvent-inaccessible core.
The core of the protein is composed of two groups of aro-
matic stacking interactions in which Phe56, Tyr173,
Phe169 and Phe176 form one group and Phe70, Phe185
and Trp187 form another. This distribution emphasizes
the hydrophobic nature of helix D that donates all of the
aromatics to these groupings, with the exception of Phe56
(AB loop) and Phe70 (B helix). 
The N-terminal loop preceding helix A (Gly4–Glu9) is
tethered to the C terminus of helix C by one of the two
disulphide bridges (Cys6 and Cys127). The second disul-
phide bridge, between Cys49 and Cys167, anchors the
start of the AB loop to the N-terminal region of helix D.
The AB loop itself consists of two separate α-helical
regions running from Pro43 to Arg46 and Glu59 to Gly64.
Residues between these two helical regions adopt an
extended conformation and pack closely against helix D.
By contrast, the second two loops (BC and CD) are less
closely associated with the core structure. The BC loop
protrudes above the four-helix bundle and exhibits higher
than average B factors. Despite this relative mobility it
does, however, contain a high percentage of regular sec-
ondary structure with a 310 helix running between residues
Ala95 and Asp97 followed by an α helix up to residue
Ser101. The long CD loop appears to be highly mobile
and could not be modelled as a single conformation.
Structural comparison with other helical cytokines
hOSM is the fourth member of the gp130 cytokine family
to be analysed structurally; crystal and/or solution struc-
tures have been reported for IL-6 [21,26], CNTF [20] and
LIF [19,27]. Structural superimpositions with these and
other four-helix bundle cytokines show that the gp130
cytokines form a distinct family both structurally and
functionally. Within the gp130 cytokine family hOSM has
the greatest structural similarity to LIF (rmsd of 2.1 Å
over 145 pairs of structurally equivalent Cα atoms). The
more distant structural similarity to the four-helix bundles
of the growth hormone family is at its best for superimpo-
sition of hOSM and erythropoietin (EPO; [28]) (rmsd of
2.8 Å for 120 pairs of structurally equivalent Cα atoms). 
The addition of hOSM to the gp130 cytokine structural
database highlights several features of potential functional
Research Article  Crystal structure of oncostatin M Deller et al. 865
Table 1
Data collection statistics.
Native EMPλ1 EMPλ2 EMPλ3
Wavelength (Å) 0.979273 1.00914 0.826516 1.00669
Unit cell 
a,b,c (Å) 35.8, 53.1, 106.8 35.9, 53.3, 106.7
α = β = γ (°) 90 90
Resolution range (Å) 25–2.2 25–2.6
Total reflections 43,901 24,040 26,223 24,159
Unique reflections 10,513 11,650 12,069 11,691
Redundancy 4.2 2.1 2.2 2.1
Completeness (%) 96.5 (98.2) 96.4 (63.1) 99.9 (100) 96.8 (66.7)
<I/σ(I)> 13.2 (4.3) 12.1 (2.9) 12.5 (4.7) 12.3 (3.3)
Rmerge (%) 8.3 (37.6) 4.6 (18.7) 4.6 (16.4) 4.3 (17.3)
EMPλ denotes MAD data collected from EMP-derivatised hOSM. Rmerge = Σ|I–<I>|/Σ<I>. Values in parentheses correspond to the highest
resolution shell (2.66–2.60 Å for EMP, 2.25–2.20 Å for native). 
Table 2
Refinement statistics.
Resolution range (Å) 20–2.2 (2.28–2.20)
Rcryst (%) 20.5 (27.1)
Rfree (%) 26.1 (33.6)
Completeness
working set (%) 86.1 (81.0)
test set (%) 9.9 (8.6)
No. of reflections (F > 0)
working set 9410 (870)
test set 1082 (92)
No. of non-hydrogen atoms
protein 1319
water 116
Rmsd from ideality
bond lengths (Å) 0.0147
bond angles (Å) 1.7997
dihedrals (°) 19.8882
improper (°) 1.0381
Average B factors
mainchain (Å2) 27.1
sidechain (Å2) 32.4
water (Å2) 38.4
all atoms (range) (Å2) 30.5 (6.3–84.9)
Rcryst = Σ||Fobs|–|Fcalc||/Σ|Fobs|. Rfree is as for Rcryst but calculated using a
10% test set of reflections excluded from the refinement. Values in
parentheses correspond to the highest resolution shell (2.28–2.20 Å).
importance (Figure 2). First, the kinked helix A is
revealed as a distinctive feature not just of the gp130
cytokines but also specifically of the members of the
family of cytokines that bind to LIFR; IL-6 is the sole
gp130 cytokine lacking this feature (Figures 1a,2a). The
kink results in a repositioning of the C-terminal end of
helix A relative to the ‘top’ of the four-helix bundle, a
region carrying the major epitope for LIFR, and OSMR,
binding (at the start of helix D). This feature is therefore
suggestive of the positioning of the C-terminal end of
helix A impacting on LIFR and OSMR binding. Con-
versely, the positioning of the N-terminal portion of
helix A, which is implicated in gp130 binding, is relatively
conserved across all members of the family.
In general, functional studies on the gp130 cytokines have
implicated the helices, rather than the connecting loops,
as having the dominant role in ligand binding. Comparison
of loop structures between family members appears to
bear this out as there are few clearly conserved characteris-
tics. Each crystal structure, except LIF, indicates highly
flexible regions in the long interhelix loops; however,
these vary in location between the AB loop in CNTF and
IL-6, and the CD loop in CNTF and hOSM. Similarly the
positioning of disulphides tethering loop regions to the
core four-helix bundle is not conserved. It has been noted,
however, that the positioning, relative to helix D, of the
N-terminal portion of the AB loop in LIF differs from that
in the distantly related four-helix bundle cytokines [19].
The current structural comparisons may point to some
functional correlation of this feature with LIFR binding as
both LIF and hOSM have a disulphide bridge anchoring
an α-helical N-terminal portion of the AB loop to the top
of helix D (Figure 2a). 
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Figure 1
The structure of hOSM. (a) Refined
coordinates and 2|Fo|–|Fc|αcalc electron-density
map of hOSM contoured at 1σ showing
density for the kinked region of helix A centred
on Thr27. CNTF and LIF also have kinks owing
to disruption of the mainchain hydrogen
bonding around residues Thr32 and Ser36,
respectively [19,20]. Both these residues bind
water molecules through the Oγ1 atom to
provide a substitute hydrogen-bond network
similar to the pattern observed here for hOSM
involving residue Thr27. (b) Ribbon diagram of
hOSM coloured from blue at the N terminus
through to red at the C terminus. Disulphide
bonds are represented as ball-and-stick
models with the sulphur atoms highlighted as
yellow spheres. The transparent dotted section
represents the CD loop as observed in LIF.
(c) Stereodiagram of the Cα trace for hOSM. 
Sequence conservation across the gp130 cytokines is rela-
tively low (i.e., typically some 20% sequence identity);
therefore very limited conservation of surface character is
to be expected. Figures 2b and 2c illustrate a comparison
of the surface characteristics in two regions of functional
significance; for both regions there is notable conservation
between three of the four gp130 cytokines. At the puta-
tive gp130-binding region involving helix A (Figure 2b),
CNTF exhibits a significantly different electrostatic
surface potential, whereas for the putative LIFR binding
site 3 on the top of the four-helix bundle (Figure 2c), IL-6
is the outlier.
Site-directed mutagenesis of hOSM
A panel of alanine scanning mutants of hOSM was gener-
ated in order to identify critical residues involved in recep-
tor recognition. The selection of residues for mutagenesis
was initially on the basis of a structural model of hOSM
(KRH and JKH, unpublished observations) derived using
the crystal coordinates of human LIF (hLIF; Protein Data
Bank [PDB] ID 1EMR) as a template and previously pub-
lished work on the location of receptor-recognition epi-
topes in human LIF [24] and CNTF [29]. Only mutation
of those residues that proved to exhibit significant solvent
exposure (Table 3) in the crystal structure of hOSM are
considered here.
Mutant proteins were tested for their ability to inhibit the
binding of biotin-labelled hOSM to immobilised human
gp130 or human LIFR ectodomains in solid-phase
binding assays (Figure 3). It was not possible to analyse
binding to hOSMR in this assay format owing to the sig-
nificantly reduced affinity of hOSM for OSMR compared
to LIFR [18]. Mutant proteins were also tested for their
ability to promote the multiplication of BAF cells trans-
fected with either human LIFR/human gp130 [24] or
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Figure 2
Structural comparisons. (a) From left to right
the structures of human OSM, LIF (PDB entry
code 1EMR), CNTF (1CNT) and IL-6 (1ALU)
are shown in equivalent orientations. Each is
represented as a ribbon coloured blue at the N
terminus through to red at the C terminus.
Helix A (blue) is kinked in OSM, LIF and CNTF
whereas helix C (light green/yellow) is only
significantly kinked in OSM. Of the interhelical
loops, only the relatively short BC loop is well
determined in all the structures. This region in
hOSM has a five-residue insertion that
protrudes from the top of the four-helix bundle.
Both LIF and hOSM have a disulphide bridge
anchoring an α-helical N-terminal portion of the
AB loop to the top of helix D, whereas in IL-6
the loop is anchored to helix B. The AB loop in
CNTF lacks any such tether and was thus too
mobile to be accurately modelled in the crystal
structure. The CD loop has not been fully
modelled for hOSM and CNTF, although the
orientation of residues preceding this loop
suggests a similar route is taken to that of LIF,
IL-6 and CNTF. (b) Comparison of surface
charge between hOSM, LIF, CNTF and IL-6.
Blue denotes positive and red negative;
electrostatic potential is contoured at ±8.5 kT
using the program GRASP [53]. The
orientation is as in (a). (c) Surface charge
comparisons are displayed as in (b) but viewed
directly onto the top of the four-helix bundle.
human OSMR/human gp130. The results for each mutant
are summarised in Table 3 and data from selected mutants
are shown in Figure 3.
Identification of site 2
The interaction of hLIF with gp130 (via site 2) has been
previously shown to depend on a cluster of adjacent
amino acids in the A and C helices, although the relative
significance of each amino acid could not be determined
[24]. This issue can be addressed by analysis of hOSM
which binds to gp130 with higher affinity than hLIF.
Alanine mutations in the individual amino acids compris-
ing the topologically equivalent region of hOSM
revealed that the interaction between hOSM and gp130
was critically dependent upon the identity of four struc-
turally adjacent solvent-exposed residues, Gln20, Gly120
and Asn124 (Figure 3a), and, to a lesser degree, Gln16
(Table 3). Each mutant exhibited equivalent activity to
WT hOSM in the ability to interact with LIFR (data not
shown), but greatly reduced activity in the ability to bind
gp130 or stimulate the multiplication of gp130/LIFR
(Figure 3b) or gp130/OSMR (Figure 3c) transfected BAF
cells. A comparable rank order of activity was observed in
both gp130-based solid-phase assays and bioassays; the
mutant Asn124Ala exhibited the greatest reduction in
activity followed by Gly120Ala and Gln20Ala. We also
constructed a mutant in which Gly120 was replaced by
tyrosine (Gly120Tyr) thereby emulating the identity of
the equivalent residue in CNTF that binds gp130 with
very low affinity. This mutant also exhibited reduced
ability to bind gp130 and stimulate the multiplication of
transfected BAF cells and was significantly less active
than the mutant Gly120Ala in both assay formats
(Figures 3a–c). Collectively, these findings reveal that
the interaction of hOSM with gp130, the site 2
epitope, is governed by four residues located in a cluster
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Table 3
Mutagenesis data for hOSM.
Location/mutant Site RSA (%)* Receptor-binding assays Ba/F3 cell-survival assays
gp130 LIFR LIFR/gp130 hOSMR/gp130
Wild-type – – 1.0 1.0 1.0 1.0
N terminus of helix D
F160A 3 65 1.1 >100 >10,000 >10,000
K163A 3 42 0.9 >100 >100 >10,000
F160A/K163A 3 – 1.0 >100 >10,000 >10,000
N-terminal loop
S7A 2 100 1.1 0.9 0.8 0.5
K8A 2 8 0.8 1.1 0.8 0.5
E9A 2 96 1.2 0.8 1.4 1.2
N terminus of helix A
Y10A 2 35 3.4 7.2 2.1 0.9
R11A 2 74 1.0 1.9 0.8 0.5
V12A 2 55 1.0 1.2 0.7 0.7
Q16A 2 56 75.0
Q18 2 36 4.0 5.0 1.2 1.1
K19 2 79 1.0 2.0 1.4 2.0
Q20A 2 27 90.0 1.0 20.0 30.0
D22A 2 40 1.0 1.0 0.8 1.0
L23A 2 61 3.0 6.7 2.5 5.0
D26A 2 63 4.0 5.0 3.0 4.1
Helix C
M113A 2 66 0.7 1.0 1.0 1.0
P116A 2 52 0.7 2.3 1.0 0.9
N117A 2 29 2.0 1.0 2.6 8.0
L119A 2 46 1.7 2.2 1.2 1.7
G120A 2 76 >100 1.8 60.0 60.0
G120Y 2 76 >100 1.8 >10,000 >10,000
N123A 2 61 8.0 1.0 3.3 10.0
N124A 2 31 >100 1.0 >10,000 >10,000
*RSA, the relative solvent accessibility of the sidechain. Mutants were
tested for inhibition of binding to immobilized gp130 and hLIFR.
Activity is expressed as the ratio IC50 mutant/IC50 WT hOSM. IC50
refers to the concentration of mutant or WT protein required to elicit
50% inhibition of binding of WT biotinylated hOSM. Mutants were also
tested for biological activity on Ba/F3 cells transfected with
gp130/LIFR or hOSMR/gp130. Activity is expressed as the ratio EC50
mutant/EC50 WT hOSM. EC50 refers to the concentration of mutant or
WT hOSM required to elicit a response equivalent to 50% of the
maximal response to hOSM.
on the A and C helices (Figure 4). Of these four residues
the most significant, in terms of the consequences of
alanine substitution, is Asn124 (in helix C) followed by
Gly120 and Gln20. This study also reveals that Gly120
plays a critical role in receptor recognition, in that a
single substitution to the bulky tyrosine residue (found
in CNTF) almost completely ablates the ability of
hOSM to interact with gp130.
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Figure 3






























 














 
 
 
 
 
































































                  
                          
                 
                        


















Structure
(a) (d)
(b) (e)
(c) (f)
Functional binding data for hOSM muteins. (a) Competitive inhibition
of biotinylated OSM binding to gp130–Fc by site 2 OSM muteins.
(b) Biological activity of OSM muteins in the Ba/F3–LIFR/gp130
assay. (c) Biological activity of OSM muteins in the
Ba/F3–OSMR/gp130 assay. (d) Competitive inhibition of biotinylated
OSM binding to LIFR–Fc by site 3 OSM muteins. (e) Biological activity
of OSM muteins in the Ba/F3–LIFR/gp130 assay. (f) Biological activity
of OSM muteins in the Ba/F3–OSMR/gp130 assay. 
Identification of site 3
The location of residues that govern the interaction with
LIFR (site 3) has been defined for hLIF [24] and CNTF
[29]. These comprise a conserved, solvent-exposed,
phenylalanine and lysine pair located at the N-terminal
end of helix D. These two residues are conserved in all
cytokines that bind LIFR [19], including hOSM (Phe160
and Lys163). The availability of a high-resolution structure
of hOSM now allows examination of the mechanism by
which hOSM, unlike hLIF, is able to bind both LIFR and
OSMR, and therefore the extent to which the site 3 recog-
nition mechanism for different receptors is conserved. Two
single point substitutions, Phe160Ala and Lys163Ala, and
the compound mutant, were tested for biological activity in
the assay systems described above (Figures 3d–f; Table 3).
Whereas all three mutants exhibited comparable activity to
WT hOSM in their ability to interact with gp130 (data not
shown), both point mutants and the compound mutant
were unable to interact with LIFR (Figure 3d; Table 3).
Analysis of the effect of these mutations on the ability to
stimulate the multiplication of transfected BAF cells
(Figures 3e,f) revealed that for both LIFR- and OSMR-
dependent BAF cells, mutations of either Phe160 or
Lys163 resulted in a dramatic loss of activity.
These findings show that the ability of hOSM to interact
with LIFR and OSMR is critically dependent upon the
identity of this pair of conserved residues and that the
mechanism of interaction with both LIFR and OSMR is
conserved. This implies that the difference in receptor
specificity between hLIF and hOSM and mOSM and
hOSM is the result of structural differences between these
ligands in the vicinity of the core Phe–Lys motif.
Discussion
The gp130 family of cytokines represents a situation in
which ligands exhibit both communality and divergence
in ligand-recognition properties. The crystal structure of
hOSM reported here represents an important advance in
understanding the molecular basis of this receptor speci-
ficity. When combined with the previously reported struc-
tures of murine, human and inter-species chimeric LIF
(PDB entries 1LKI, 1EMR, 1A7M), as well as CNTF
(1CNT), it is possible to define structural features that
represent shared recognition properties, such as the inter-
action with gp130 and LIFR and divergent properties
such as the interaction between hOSM and OSMR or the
requirement for the accessory CNTF receptor for the
interaction between CNTF and gp130.
All gp130 cytokine structures reported to date, including
hOSM, conform to a similar overall structural fold. This is
the archetypal four-helix bundle form of the long-chain
cytokine class [30]. On the basis of this paper, two struc-
turally distinct subfamilies can be defined within the
gp130 cytokines. All cytokines that interact with LIFR
prove to have a marked kink in the A helix. This is most
pronounced in the present hOSM structure (Figure 2).
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Figure 4
Structural mapping of binding sites 2 and 3 for hOSM. (a) Ribbon
representation of hOSM with solvent-exposed residues studied by
mutagenesis depicted in ball-and-stick representation. The solvent-
accessible surface of hOSM in the regions of (b) site 2 and (c) site 3
with areas contributed by the mutagenised residues highlighted as
coloured patches. For site 2 the orientation is as in (a) for site 3 the
view is on to the top of the four-helix bundle. Residues not implicated
in gp130 binding are in light-blue, those with some effect are yellow,
residues critical for gp130 binding are green and those critical for LIFR
binding are red. 
By contrast, in IL-6 [21], which does not interact with
LIFR, the A helix conforms to the standard hydrogen-
bonding pattern throughout its length. This indicates
that the A helix kink may represent a structural feature of
LIFR recognition. In this respect it is notable that the
LIFR contains two copies of the CHD in the extracellu-
lar domain and that the A helix kink may represent a
structural feature which permits a low-affinity interaction
with the N-terminal CHD of LIFR. The existence of
such an interaction has been inferred from homology
scanning studies of the interaction between LIF and
LIFR [31,32]. 
The interaction with gp130
The detailed mutagenesis study of hOSM reported here,
combined with earlier studies of hLIF [24], has identified
those amino acid residues that contribute the majority of
binding energy to the interaction with gp130, as defined
by the consequences of alanine scanning analysis. This
reveals a quartet of residues in the A and C helices that
form a distinct patch in the crystal structure (Figure 4). In
terms of the interaction between hOSM and gp130, the
most important residues are Asn124 and Gly120 in helix C,
with lesser contributions from Gln16 and Gln20 in helix A.
The crystal structure of the CHD of gp130 [25] combined
with mutagenesis data of gp130 ([33]; KRH, E Raulo, O
McKenzie and JKH unpublished observations) provides a
structural explanation for this interaction. The most promi-
nent feature of gp130 is a solvent-exposed hydrophobic
residue (Phe169) in an interstrand loop of the N-terminal
half of the bipartite CHD (Figure 5). The second signifi-
cant determinant of gp130 recognition is a prominent
solvent-exposed tyrosine residue (Tyr196), located close to
the junction between the two elements of the CHD, the
hydroxyl group of which faces away from the main body of
the molecule into solution (Figure 5). Inspection of the
two functional epitopes in open book format (Figure 5)
immediately suggests an explanation for the molecular
mechanism of ligand recognition. This indicates that the
exposed phenylalanine residue on gp130 may be docked
into the hydrophobic ‘dimple’ formed on the hOSM
surface from the Cα backbone of Gly120. In this configu-
ration the hydroxyl group of gp130 Tyr196 would be able
to hydrogen bond with the exposed amide group of
Asn124 from hOSM. This explanation is consistent with
mutagenesis of hOSM Gly120 reported here in which sub-
stitution to alanine, which has a relatively small non-polar
sidechain, has less effect on binding than substitution to
the bulkier tyrosine residue (Table 3). The substitution of
a bulky sidechain would be expected to occlude the non-
polar dimple and thereby inhibit docking of the Phe169 of
gp130 and formation of the hydrogen bond between the
Tyr196 of gp130 and the Asn124 of hOSM.
This proposed mode of docking between hOSM site 2 and
gp130 has strong similarities to the interaction between
growth hormone and the growth hormone receptor [23]
and EPO/EPO receptor [28]. In both these cases the site 2
interaction also involves burying a bulky, solvent exposed,
aromatic residue in a hydrophobic patch formed from the
Cα backbone of helix C. This suggests that the basic
site 2 recognition mechanism may exhibit strong structural
similarities across the whole cytokine/receptor family. The
point of divergence between gp130 and these other
systems appears to arise from the use of polar interactions,
for example the putative Tyr100–Asn124 hydrogen bond,
that contribute additional specificity to complex forma-
tion. Thus a major contribution to binding affinity from a
distinctive hydrophobic interaction is conserved whilst
specificity is controlled through polar interactions. A
similar pattern of conservation has recently been noted for
a second set of cytokine–receptor interactions, those of the
tumour necrosis factor (TNF) like cytokines with their
cognate receptors [34].
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Figure 5
Complimentarity between the interaction
surfaces of hOSM and gp130. The solvent-
accessible surfaces of site 2 on hOSM (left)
and the cognate binding site on gp130
(right) are displayed with areas contributed
by residues implicated in binding highlighted
as coloured patches. The orientation for
hOSM site 2 is rotated 90° from that in
Figure 4 whereas gp130 is rotated by 180°
from its orientation relative to hOSM in the
putative interaction complex, as in the
opening of a book.
This hypothesis also suggests why CNTF interacts with
gp130 at a very much lower affinity than either LIF or
hOSM. In CNTF the equivalent residue to Gly120 is a
tyrosine which, as argued above, would be predicted to
disrupt the core interaction. The employment of the acces-
sory receptor CNTF-R in this scheme is required to com-
pensate for this loss of affinity by introducing additional
sites of receptor–receptor interaction into the complex. 
The interaction with LIFR and OSMR
A distinctive feature of the gp130 cytokine family is the
use of a novel receptor recognition site 3 located at the N
terminus of helix D. This epitope engages the second sig-
nalling receptor in the complex: either LIFR/OSMR in the
case of OSM, LIF and CNTF, or gp130 in the case of IL-6
and IL-11. Previous studies [24,29] have revealed that, for
the interaction with LIFR, this site 3 epitope involves a
solvent-exposed pair of residues which are conserved in all
LIFR-binding cytokines described to date. The availabil-
ity of the crystal structure of hOSM has enabled us to
determine both the extent to which this recognition
scheme holds for additional members of the family and to
examine the involvement of this epitope in the interaction
between hOSM and OSMR. Mutagenesis of the two key
site 3 residues in hOSM, Phe160 and Lys163, reveals that
each residue is required for the interaction with both LIFR
and OSMR. This epitope (Figure 4) therefore represents a
core structural element in site 3 recognition, although the
precise significance of each residue in the epitope differs
between LIFR and OSMR. It follows that the ability of
OSM to interact with OSMR must result from either the
involvement of additional residues in the vicinity of this
epitope or the presence of residues in LIF which block
some feature of the interaction with OSMR.
It is intriguing that the structure of the site 3 recognition
epitope is similar to the site 2 recognition site of gp130:
both employ a prominent aromatic sidechain as a ‘core’
with additional affinity contributed by the sidechain of a
residue in close physical proximity. This suggests that
site 3 receptor recognition may involve a similar overall
scheme to that of site 2 except that the complementary
epitopes on receptor and ligand are reversed. This suggests
that the site 3 recognition site in LIFR, which is located in
the immunoglobulin-like domain [31,32,35], may involve
an analogous hydrophobic dimple or patch formed from
residues with small sidechains. In this respect it is notable
that alanine scanning studies of the LIFR site 3 hOSM
recognition site imply a short sequence motif with a con-
served glycine residue at its core [32].
Biological implications
The interaction of cytokine ligands with transmembrane
receptors to form signalling complexes is a major mecha-
nism for intercellular signal transduction and cell regula-
tion. The molecular specificity of the extracellular
cytokine–receptor interaction is of fundamental biologi-
cal significance as it dictates the resulting intracellular
signal-transduction processes and, accordingly, the asso-
ciated biological responses. The family of cytokines
which mediate their effects through binding to the gp130
receptor — namely oncostatin M (OSM), leukaemia
inhibitory factor, interleukins 6 and 11, cardiotrophin-1
and ciliary neurotrophic factor (CNTF) — are of partic-
ularly broad biomedical importance. Of these gp130-
binding cytokines, human OSM (hOSM) is of potential
interest for novel cancer therapeutics as well as provid-
ing a target for the treatment of inflammatory responses
in the joints and nervous system. 
The combined crystal structure and mutagenesis analy-
sis of hOSM reported here has provided important
insights into the molecular basis of biological specificity
in the gp130 cytokine system. Particular value accrues
from the structural comparisons these data now allow
with a panel of gp130 cytokines that exhibit both
common and divergent receptor-recognition properties.
The study confirms the concept [36] that receptor recog-
nition involves a conserved non-polar ‘core’ inter-
action with specificity contributed by the identity of
residues surrounding the core. This study also suggests
a second aspect to recognition specificity: the require-
ment for soluble receptors in some gp130 signalling com-
plexes (e.g. CNTF receptor in the CNTF-mediated
recognition complex) acting to compensate for low-affin-
ity core interactions by the introduction of additional
receptor–receptor interactions. Finally, this study pro-
vides the structural basis for the development of small-
molecule compounds to intervene in hOSM-mediated
signalling events.
Materials and methods
Production and expression of hOSM proteins
A 21.4 kDa fragment of mature hOSM (residues 1–187) was
expressed as a GST fusion protein using the pGex-2T expression
vector (Pharmacia). The hOSM and GST proteins were joined by a
recognition site for rhinovirus 3C protease. All OSM mutants were gen-
erated by overlap polymerase chain reaction from the pGEX–hOSM
template GST fusion using specific oligonucleotides for each mutant;
the sequences of primers used are available on request. hOSM
(1–187) and mutant proteins were expressed as GST fusions in E. coli
strain JM109. Soluble GST fusion proteins were bound to glu-
tathione–sepharose resin and the OSM protein released by overnight
cleavage with 3C protease at 37°C and purified by high-resolution gel-
filtration on a Sephadex-75 column (Pharmacia). All proteins had a
purity of greater than 80% as determined by SDS PAGE and silver
staining. Protein concentrations were determined by the Coomassie
Protein Plus assay (Bio-rad).
The identity of the purified hOSM (1–187) protein employed for crys-
tallisation was confirmed using electrospray ionisation on a Micromass
BioQ II triple, quadrapole, atmospheric pressure mass spectropho-
tometer equipped with an electrospray interface operating in the posi-
tive ion mode (Robin Aplin, Oxford Centre for Molecular Science,
Oxford). N-terminal sequencing was also carried out for 10 cycles
using an Applied Biosystems 494A/473A Sequencer (Tony Willis,
MRC Immunochemistry Unit, Oxford).
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Bioassays of hOSM mutants
Mutant forms of hOSM were tested for biological activity on the Ba/F3-
hLIFR/hgp130 cell line as described previously [24]. The BA/F3-
hOSMR/hgp130 cell line was generated by co-transfecting Ba/F3 cells
with a full-length hgp130 cDNA expressed under the control of the
cytomegalovirus (CMV) promoter in plasmid pCDNA3 and the full-length
hOSMR cDNA [15] expressed under the control of the CMV promoter in
plasmid pCDNA3. Transfected cells were cultured overnight in 50 ng/ml
IL-3 and then selected for co-expression of hgp130 and hOSMR in the
presence of 50 ng/ml hOSM. Co-expression of both receptors in co-
transfectants was confirmed by FACS analysis after staining with anti-
bodies directed against hgp130 [37] and hOSMR (KRH and JKH,
unpublished observations). Bioassays were performed as described pre-
viously [19]. All assays were performed in triplicate in at least three inde-
pendent experiments. The data presented are the results from a single
experiment, as it was noted that absolute response to defined concentra-
tions of ligand varied between different batches of cells, although the rel-
ative potencies of the WT and mutant proteins were preserved. The SEM
of triplicate determinations was always less than 15% of the mean.
Ligand-binding assays
Human gp130 and hLIFR were expressed as fusion proteins with
human Fc as described previously [24]. The fusions were purified by
protein A sepharose affinity chromatography and employed in solid-
phase ligand-binding assays using biotin-conjugated hOSM as the
tracer [24]. The ability of mutant forms of hOSM to compete with
biotin–hOSM tracer was analysed using the PRISM software package
(Graphpad Software) using a single-site binding model. 
Crystallization and derivatisation
For crystallisation trials, hOSM(1–187) was concentrated to 8 mg/ml in
50 mM Tris-HCl containing 150 mM sodium chloride, pH 7.5. Crystals
grew by vapour diffusion within 1–3 days at 22°C from hanging drops
typically comprising 2 µl of protein solution plus 2 µl of reservoir solu-
tion (30% w/v PEG 35,000, 0.25 M sodium acetate, pH 7.5). Crystals
measured approximately 0.3 × 0.2 × 0.2 mm3 and showed ordered
Bragg diffraction to 2.2 Å when exposed to synchrotron radiation. Pre-
liminary characterisation indicated that the crystals belong to the
orthogonal spacegroup P212121 with unit cell dimensions a = 35.8 Å,
b = 53.1 Å, c = 106.8 Å and α = β = γ = 90°. There is one molecule
per asymmetric unit and the crystal solvent content is ~48.0%
(Matthews coefficient, Vm = 2.3 Å/Da). Tests using a number of heavy
atom compounds highlighted EMP as a putative heavy atom derivative.
Derivatisation was carried out by soaking crystals in pre-equilibrated
drops of mother liquor containing 14 mM EMP for 16–24 h.
Data collection
MAD data were collected to a resolution of 2.6 Å from a single EMP deriv-
ative crystal on beam line BM14 at the ESRF, Grenoble, France. Crystals
were briefly passed through a cryoprotectant solution consisting of a 2 µl
drop of 30% (w/v) PEG 35,000, 0.25 M sodium acetate, pH 7.5 over-
layed with 2 µl of 30% (w/v) PEG 8000, 0.25 M sodium acetate, pH 7.5
and then flash-cooled directly in liquid propane. The crystal was main-
tained at 100K in a dry air stream and data recorded using a MAR 345
image plate detector (MAR Research, Hamburg, Germany). The mercury
LΙΙΙ edge of the derivative crystal was characterised by a fluorescence
scan and X-ray data sets collected at three wavelengths (λ = 1.00669 Å,
1.00914 Å and 0.826516 Å). A 2.2 Å resolution native data set was also
collected at the same beamline from a single cryo-cooled crystal.
Individual data sets were auto-indexed, integrated and scaled using the
programs DENZO and SCALEPACK [38]. Structure factor amplitudes
were calculated using the program TRUNCATE [39], the data sets
scaled using the program SCALEIT [40], and normalised anomalous
scattering magnitudes estimated using the program REVISE [41]. Data
collection statistics are reported in Table 1. 
Structure determination and analysis
Scaling of MAD data sets yielded maximal dispersive differences of
10.6% and maximal anomalous differences of 9.7%. The mercury sites
for the EMP derivative were determined by manual inspection of differ-
ence and anomalous Patterson syntheses and confirmed using the pro-
grams RSPS and SOLVE [42]. The sites were refined using the
program SHARP [43], and MAD phases were calculated to 2.6 Å reso-
lution (figure of merit = 0.46, phasing power = 1.84). Initial maps based
on these phases and Fobs from the EMPλ2 data set proved uninter-
pretable. Hendrickson-Lattman coefficients for SIRAS phases derived
using the EMP derivative and native data were combined with the MAD
phases. Maps based on these combined phases and the EMPλ2 Fobs
(figure of merit 0.51, phasing power = 1.90) showed improved main
chain density. Phase improvement was carried out using solvent flat-
tening, as implemented by the program SOLOMON [44], and the
structure was traced using the interactive graphics program O [45]. 
All refinement steps (positional, torsional dynamics, grouped B factor
and individual B factor) were carried out using the program CNS-
SOLVE [46]. A bulk-solvent correction was employed (solvent
density = 0.29 e/Å3, B-factor = 31.1 Å2), so allowing all data in the res-
olution range 20.0–2.2 Å to be included. In the final stages of refine-
ment 116 waters were located. The current model consists of residues
4–134 and 156–187 of the mature protein with no residues falling in
disallowed regions of the Ramachandran plot. Refinement and model
statistics are reported in Table 2. 
The quality of the final model was assessed using the program
PROCHECK [47], secondary structure assignments were calculated
using the program DSSP [48] and solvent accessibilities calculated
using NACCESS [49]. Structural superimpositions were performed
using the program SHP [50] and structural figures were produced
using BOBSCRIPT [51], RASTER3D [52], VOLUMES (R Esnouf, per-
sonal communication) and GRASP [53].
Accession numbers
Atomic coordinates for hOSM have been deposited with the PDB
(accession number 1EVS). 
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